14 completed. 14 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 14 |
| Phase 2 | 2 | Completed 2 |
Follow trebananib: new trials by email Literature Review of trebananib trials Research Report on trebananib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor Pembrolizumab, Trebananib - Advanced Solid Tumor | Phase 1 | Completed | Dana-Farber Cancer Institute | 62 | 2018-05-01 | 2026-07-01 |
| Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer AMG 386, AMG 386 Placebo, Pemetrexed - Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Amgen | 36 | 2012-08-01 | 2016-06-03 |
| AMG 386 Drug-Drug Interaction Study With Paclitaxel AMG 386, Paclitaxel - Advanced Solid Tumors | Phase 1 | Completed | Amgen | 35 | 2012-07-01 | 2014-09-23 |
| Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus - Adult Solid Neoplasm, Lung Carcinoid Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 21 | 2012-03-01 | 2015-10-06 |
| Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Laboratory Biomarker Analysis, Pharmacological Study - Central Nervous System Neoplasm, Solid Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 37 | 2012-02-01 | 2016-10-03 |
| Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia trebananib, cytarabine, laboratory biomarker analysis - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 1 | Completed | Roswell Park Cancer Institute | 24 | 2011-10-31 | 2022-09-13 |
| A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function AMG 386 + Paclitaxel, AMG 386 - Advanced Solid Tumors, Kidney Disease | Phase 1 | Completed | Amgen | 35 | 2011-09-19 | 2017-11-06 |
| Amgen 386 for Recurrent Glioblastoma Amgen 386, Bevacizumab - Glioblastoma Multiforme | Phase 1 / Phase 2 | Completed | Dana-Farber Cancer Institute | 48 | 2010-12-01 | 2017-07-02 |
| Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer AMG 386, paclitaxel and carboplatin - Carcinoma, Fallopian Tube Cancer | Phase 1 | Completed | Amgen | 27 | 2010-11-01 | 2015-10-14 |
| A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386 ) in Adult Japanese Participants With Advanced Solid Tumors Trebananib 3 mg/kg, Trebananib 10 mg/kg, Trebananib 30 mg/kg - Neoplasms, Advanced Solid | Phase 1 | Completed | Takeda | 18 | 2009-06-01 | 2015-09-22 |
| Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer AMG 386 30 mg/kg, Paclitaxel and Trastuzumab, AMG 386 30 mg/kg, Capecitabine and Lapatinib, AMG 386 10 mgkg, Paclitaxel and Trastuzumab - Breast Cancer, Breast Neoplasms | Phase 1 | Completed | Amgen | 65 | 2009-03-09 | 2022-11-08 |
| AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR A1: AMG 386 10 mg/kg + Liposomal doxorubicin, A3: AMG 386 15mg/kg + Liposomal doxorubicin, B1: AMG 386 10 mg/kg + Topotecan - Cancer, Carcinoma | Phase 1 | Completed | Amgen | 103 | 2009-01-01 | 2015-09-29 |
| To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib. Sorafenib, AMG 706, AMG 386 - Advanced Solid Tumors | Phase 1 | Completed | Amgen | 88 | 2005-12-01 | 2017-02-08 |
| Study Evaluating AMG 386 in Adult Patients With Advanced Solid Tumors AMG 386 - Tumors | Phase 1 | Completed | Amgen | 2010-08-20 |
Neoplasms (4) · Carcinoma (3) · Neoplasm Metastasis (3) · Ovarian Neoplasms (3) · Fallopian Tube Neoplasms (2) · Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Central Nervous System Neoplasms (1) · Colorectal Neoplasms (1) · Congenital Abnormalities (1) · Glioblastoma (1) · Glioma (1) · Kidney Diseases (1)
Amgen (8) · Dana-Farber Cancer Institute (2) · National Cancer Institute (NCI) (2) · Roswell Park Cancer Institute (1) · Takeda (1)
United States (9) · Belgium (4) · Australia (3) · Canada (3) · Spain (2) · France (1) · Greece (1)
David Reardon, MD (1) · Eunice Wang (1) · Philippe Bedard (1) · Sarah Leary (1) · Stephen Hodi, MD (1)
PMID 22210018, PMID 23124648, PMID 25037684
U01CA132123 (1), UM1CA097452 (1), UM1CA186644 (1)